Table 1.

Baseline demographics for adjuvant ipilimumab patients.

Patient ID	Age	Gender	Definitive Treatment Modality	Additional Local Therapy Prior to Enrollment	Size (mm)	T Stage *****	DecisionDx UM Class	Days Elapsed ***	Number of Cycles of Ipilimumab	Ipilimumab Dose (mg/kg)	Baseline LDH (ULN 618 IU/L)	Reason for Discontinuation
1	35	M	Brachytherapy	Yes, thermotherapy	16 × 15 × 8	3	2	204	7	3	386	Completed Therapy
2	45	M	Brachytherapy	-	12 × 10 × 3	1	2	63	5	3	421	4th induction dose and last maintenance dose held due to Grade 3 transaminitis and Grade 2 fatigue and hypothyroidism
3	58	F	Brachytherapy *	Yes, avastin	15 × 12 × 4	2	2	77	6	3	523	3rd induction dose held due to Grade 3 rash
4	74	F	Brachytherapy	-	13 × 13 × 4.6	2	2	161	7	10	552	Completed therapy
5	60	M	Proton beam therapy	-	21 × 17 × 10.1	4	2	111	2	10	402	Only 2 doses given due to Grade 4 vasculitis
6	59	F	Brachytherapy	Yes, avastin	13 × 10 × 4.4	2	2	317	2	10	428	Only 2 doses given due to Grade 3 diarrhea, Transaminitis
7	65	M	Enucleation	-	14 × 12 × 11	3	2	83	7	10	357	Completed therapy
8	50	F	Brachytherapy	-	6 × 5	N/A	2	179	6	10	287	3rd induction dose held secondary to Grade 3 hypophysitis
9	57	M	Brachytherapy	**	8 × 8.1 × 2.7	1	2	67	5	10	417	4th induction dose held secondary to Grade 2 hypophysitis; last maintenance dose held due to Grade 3 transaminitis
10	58	M	Enucleation	-	15 × 14 × 9	3	2	153	7	10	592 ****	Completed therapy

* In combination with cryotherapy and radiation; ** received intraocular avastin prior to diagnosis of uveal melanoma; *** from definitive therapy to initiation of ipilimumab; **** LDH obtained after initiation of therapy; ***** all tumors located within the choroid and/or ciliary body.